Metabolism of BYZX in Human Liver Microsomes and Cytosol: Identification of the Metabolites and Metabolic Pathways of BYZX

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Yu, Lushan ^a   Jiang, Yan ^a   Wang, Lu ^a   Sheng, Rong ^a   Hu, Yongzhou ^a   Zeng, Su ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; [2 [4 [(DIETHYLAMINO)METHYL]BENZYLIDENE] 5,6 DIMETHOXY 2,3 DIHYDROINDEN ONE]; ALPHA NAPHTHOFLAVONE; BENZYLIDENEACETONE; BYZX; CHOLINESTERASE INHIBITOR; CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DICOUMAROL; DIETHYLDITHIOCARBAMIC ACID; DRUG METABOLITE; INDOMETACIN; KETOCONAZOLE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; QUERCETIN; QUINIDINE; SERTRALINE; SULFAPHENAZOLE; TICLOPIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL MODIFICATION; CHEMICAL REACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DESETHYLATION; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG ISOLATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROGENATION; LIQUID CHROMATOGRAPHY; LIVER CYTOSOL; LIVER MICROSOME; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; RAT; TANDEM MASS SPECTROMETRY;

ARYL HYDROCARBON HYDROXYLASES; BENZYLIDENE COMPOUNDS; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; CYTOSOL; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; HYDROGEN; INDENES; INDOMETHACIN; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; METABOLIC NETWORKS AND PATHWAYS; MICROSOMES, LIVER;

EID: 84875530722     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059882     Document Type: Article

References (35)

1. Sheng R, Lin X, Li J, Jiang Y, Shang Z, et al. (2005) Design, synthesis, and evaluation of 2-phenoxy-indan-1-one derivatives as acetylcholinesterase inhibitors. Bioorg Med Chem Lett 15: 3834-3837.
2. Sheng R, Xu Y, Hu C, Zhang J, Lin X, et al. (2009) Design, synthesis and AChE inhibitory activity of indanone and aurone derivatives. Eur J Med Chem 44: 7-17.
3. Zhang J, Zhu D, Sheng R, Wu H, Hu Y, et al. (2009) BZYX, a novel acetylcholinesterase inhibitor, significantly improved chemicals-induced learning and memory impairments on rodents and protected PC12 cells from apoptosis induced by hydrogen peroxide. Eur J Pharmacol 613: 1-9.
4. Hellriegel ET, Bjornsson TD, Hauck WW, (1996) Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 60: 601-607.
5. Gillette JR, Mitchell JR, Brodie BB, (1974) Biochemical mechanisms of drug toxicity. Annu Rev Pharmacol 14: 271-288.
6. Knowles SR, Uetrecht J, Shear NH, (2000) Idiosyncratic drug reactions: the reactive metabolite syndromes. The Lancet 356: 1587-1591.
7. Liebler DC, Guengerich FP, (2005) Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov 4: 410-420.
8. Lee MS, Zhu M (2011) Mass spectrometry in drug metabolism and disposition: basic principles and applications. Hoboken, N.J.: John Wiley.
9. Xia ZL, Ying JY, Sheng R, Zeng S, Hu Y, et al. (2007) In vitro metabolism of BYZX in human liver microsomes and the structural elucidation of metabolite by liquid chromatography-mass spectrometry method. J Chromatogr B Analyt Technol Biomed Life Sci 857: 266-274.
10. Tomalik-Scharte D, Fuhr U, Hellmich M, Frank D, Doroshyenko O, et al. (2011) Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metab Dispos 39(5): 927-32.
11. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31: 815-832.
12. Clarke S, (1998) In vitro assessment of human cytochrome P450. Xenobiotica 28: 1167-1202.
13. Chen X, Pan LQ, Naranmandura H, Zeng S, Chen SQ, (2012) Influence of various polymorphic variants of cytochrome P450 Oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6. PloS one 7: e38495.
14. Wang XW, Zeng S, (2009) Heterogenous expression and activity analysis of human cytochrome P450 3A4 mutants CYP3A4. 3, CYP3A4. 4, CYP3A4. 5 and CYP3A4. 18. Chin J Pharmacol Toxicol 23: 456-463.
15. Titus MA, Gregory CW, Ford III OH, Schell MJ, Maygarden SJ, et al. (2005) Steroid 5α-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 11: 4365-4371.
16. Kokate TG, Banks MK, Magee T, Yamaguchi SI, Rogawski MA, (1999) Finasteride, a 5α-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J Pharmacol Exp Ther 288: 679-684.
17. Ortiz de Montellano PR, Mathews J, (1981) Autocatalytic alkylation of the cytochrome P-450 prosthetic haem group by 1-aminobenzotriazole. Isolation of an NN-bridged benzyne-protoporphyrin IX adduct. Biochemical J 195: 761-764.
18. Ortiz de Montellano PR, Mathews JM, Langry KC, (1984) Autocatalytic inactivation of cytochrome P-450 and chloroperoxidase by 1-aminobenzotriazole and other aryne precursors. Tetrahedron 40: 511-519.
19. Yu LS, Lu SJ, Lin YJ, Zeng S, (2007) Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem Pharmacol 73: 1842-1851.
20. Kobayashi K, Ishizuka T, Shimada N, Yoshimura Y, Kamijima K, et al. (1999) Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos 27: 763-766.
21. Obach RS, Cox LM, Tremaine LM, (2005) Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 33: 262-270.
22. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, et al. (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37: 4137-4147.
23. Tracy TS, (2003) Atypical enzyme kinetics: their effect on in vitro-in vivo pharmacokinetic predictions and drug interactions. Curr Drug Metab 4: 341-346.
24. Galetin A, Clarke SE, Houston JB, (2003) Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. Drug Metab Dispos 31: 1108-1116.
25. Wang RW, Newton DJ, Liu N, Atkins WM, Lu AYH, (2000) Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28: 360-366.
26. Atkins WM, (2004) Implications of the allosteric kinetics of cytochrome P450s. Drug Discov Today 9: 478-484.
27. Ekins S, Ring B, Binkley S, Hall S, Wrighton S, (1998) Autoactivation and activation of the cytochrome P450s. Int J Clin Pharm Therapeutics 36: 642-651.
28. Ishida M, Kitamura S, Tatsumi K, (1996) Purification of an α, β-ketoalkene double bond reductase from Salmonella typhimurium. Biochem Mol Biol Int 39: 1157-1165.
29. Kitamura S, Kohno Y, Okamoto Y, Takeshita M, Ohta S, (2002) Reductive metabolism of an α, β-ketoalkyne, 4-phenyl-3-butyn-2-one, by rat liver preparations. Drug Metab Dispos 30: 414-420.
30. Kohno Y, Kitamura S, Sanoh S, Sugihara K, Fujimoto N, et al. (2005) Metabolism of the α, β-unsaturated ketones, chalcone and trans-4-phenyl-3-buten-2-one, by rat liver microsomes and estrogenic activity of the metabolites. Drug Metab Dispos 33: 1115-1123.
31. Kitamura S, Tatsumi K, (1990) Purification of NADPH-linked alpha,beta-ketoalkene double bond reductase from rat liver. Arch Biochem Biophys 282: 183-187.
32. Lindstrom TD, Whitaker GW, (1984) Saturation of an alpha, beta-unsaturated ketone: a novel xenobiotic biotransformation in mammals. Xenobiotica 14: 503-508.
33. Itoh K, Yamamoto K, Adachi M, Kosaka T, Tanaka Y, (2008) Leukotriene B4 12-hydroxydehydrogenase/15-ketoprostaglandin Delta 13-reductase (LTB4 12-HD/PGR) responsible for the reduction of a double-bond of the alpha,beta-unsaturated ketone of an aryl propionic acid non-steroidal anti-inflammatory agent CS-670. Xenobiotica 38: 249-263.
34. Chen W, Zouboulis CC, Orfanos C, (1996) The 5α-Recluctase System and Its Inhibitors. Dermatology 193: 177-184.
35. Thigpen A, Silver R, Guileyardo J, Casey ML, McConnell J, et al. (1993) Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 92: 903-910.